This document provides information on the top 10 holdings of the HAN-GINS Indxx Healthcare Innovation UCITS ETF as of 21st March 2019. The largest holding is Illumina, a developer of life science tools and DNA sequencing systems, at 5.5%. The other top holdings include Boston Scientific, Medtronic, Intuitive Surgical, Biogen and others in the medical device and healthcare industries. Contact information is provided for HANetf.

1. HAN-GINS Indxx Healthcare Innovation UCITS
ETF

2. Illumina is a leading developer, manufacturer, and marketer of life science
tools and integrated systems for large-scale analysis of genetic variation and
function. Illumina sells a number of high-throughput DNA sequencing
systems, also known as DNA sequencers, based on technology developed by
Solexa
5.5%
As of 21st March 2019

3. Boston Scientific, is a manufacturer of medical devices used in interventional
medical specialties, including interventional radiology, interventional
cardiology, peripheral interventions, neuromodulation, neurovascular
intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy,
oncology, urology and gynecology.
5.2%
As of 21st March 2019

4. Medtronic is a medical technology and services company.The company
develops, manufactures and markets its medical devices and technologies to
hospitals, physicians, clinicians and patients in approximately 160 countries.
The Company operates in four segments: Cardiac andVascular Group,
Minimally InvasiveTechnologies Group, RestorativeTherapies Group and
Diabetes Group.
5.0%
As of 21st March 2019

5. Intuitive was founded in 1995 to create innovative, robotic-assisted systems
that help empower doctors and hospitals to make surgery less invasive than
an open approach.
5.0%
As of 21st March 2019

6. Biogen Inc. is an American multinational biotechnology company based in
Cambridge, Massachusetts, specializing in the discovery, development, and
delivery of therapies for the treatment of neurodegenerative, hematologic,
and autoimmune diseases to patients worldwide.
5.0%
As of 21st March 2019

7. Edwards Lifesciences is a leader in the field of tissue replacement heart
valves and repair products. Edwards also manufactures products for vascular
therapy along with hemodynamic monitoring devices for measuring
cardiovascular performance during surgery and in the ICU.
4.9%
As of 21st March 2019

8. Regeneron is a biotechnology company that invents life-transforming medicines
for people with serious diseases. Current medicines and pipeline are designed to
help patients with eye diseases, allergic and inflammatory diseases, cancer,
cardiovascular and metabolic diseases, neuromuscular diseases, infectious
diseases and rare diseases.
4.8%
As of 21st March 2019

9. MicroPort is a global medical device developer and manufacturer that is
headquartered in Shanghai, China. It designs and produces products for a
range of medical fields including cardiology, interventional radiology,
orthopedics, electrophysiology, and surgical management. MicroPort is
considered to be among the top 100 medical device companies in 2018 and
was selected to be the 2017 China Innovative Medical Device Company
4.3%
As of 21st March 2019

10. AgilentTechnologies is an American public research, development and
manufacturing company established in 1999.The company provides
analytical instruments, software, services and consumables for the entire
laboratory workflow. Agilent focuses its products and services on six markets:
food, environmental and forensics, pharmaceutical, diagnostics, chemical
and energy, and research.
3.9%
As of 21st March 2019

11. Zimmer Biomet innovations help treat disorders of, or injuries to, the bones,
joints, and supporting soft tissues. Zimmer designs, develops, manufactures
and markets orthopaedics products, including knee, hip, shoulder, elbow,
foot and ankle artificial joints and dental prostheses.
3.9%
As of 21st March 2019

12. HANetf
101 Finsbury Pavement
Moorgate
London
EC2A 1RS
www.hanetf.com
+44 (0) 203 657 2820
UK Sales:
David.Patterson@hanetf.com
+44 (0) 207 657 2818
Italian Sales:
Edoardo.Passaretti@hanetf.com
+39 328 175 8183
German Sales:
Andre.Voinea@hanetf.com
+44 (0) 203 657 2828
CONTACT US
HANetf
@HANetf
12

13. 13
IMPORTANT INFORMATION
The content in this document is issued by his document is issued by HANetf Limited (“HANetf”), an appointed representative of Mirabella Advisers LLP, which is authorised and regulated by
the Financial Conduct Authority (“FCA”). For professional clients only. Past performance is not a reliable indicator of future performance. Any historical performance included on this
document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy
would have been. Back tested performance is purely hypothetical and is provided on this document solely for informational purposes. Back tested data does not represent actual performance
and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements.
Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice. These products may not
be available in your market or suitable for you. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or
make any investment. An investment in an ETF is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETFs involve
numerous risks including among others, general market risks relating to the relevant underlying index, exchange rate risks, interest rate risks, inflationary risks, liquidity risks and legal and
regulatory risks.
The information contained on this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the
United States or any province or territory thereof, where none of the Issuers or their products are authorised or registered for distribution and where no prospectus of any of the Issuers has
been filed with any securities commission or regulatory authority. No document or information on this document should be taken, transmitted or distributed (directly or indirectly) into the
United States. None of the Issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or
qualified under any applicable state securities statutes. The products discussed on this document are issued by HANetf ICAV.
This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or
sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could
differ materially from those anticipated in such statements. Therefore, readers are cautioned not to place undue reliance on these forward-looking statements. HANetf ICAV is an open-
ended Irish collective asset management vehicle which is constituted as an umbrella fund with segregated liability between sub-funds and with variable capital organised under the laws of
Ireland and authorised by the Central Bank of Ireland (“CBI”). Investors should read the prospectus of HANetf ICAV (“HANetf Prospectus”) before investing and should refer to the section of
the HANetf Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in the Shares.